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ABSTRACT
The metal complexes of amine-carboxyborane including copper, chromium, zinc, calcium amd cobalt were
effective hypolipidemic agents lowering both serum cholesterol and triglyceride levels significantly in mice at
8 mg/kg/day, I.P. after 16 days. The agents reduced acetyl CoA synthetase, ATP-dependent citrate lyase, acyl
CoA cholesterol acyl transferase, sn-glycerol-3-phosphate acyl transferase activities of rat liver and small
intestinal mucosa after 14 days treatment. The neutral cholesterol ester hydrolase activity was elevated by the
agents in both tissues. The metal complexes altered lipid levels in the bile of rats after treatment as well as
the bile acid composition after 14 days administration, orally. The agents blocked enterohepatic absorption of
cholesterol from rat isolated intestinal loops.
INTRODUCTION
Amine-carboxyboranes have proven to be effective hypolipidemic agents in mice I.P. and rats, orally at 5-20
mg/kg/day [1-4]. Both serum cholesterol and triglyceride levels are significantly reduced. These agents
successfully reduced VLDL and LDL cholesterol levels and elevated HDL cholesterol levels in rats. One of the
modes of action of the derivatives was the suppression of rate limiting enzyme activities of de novo synthesis
of lipids. One particular derivative tetrakis-u- (trimethylamine-boranecarboxylato)-bis(trimethylamine-
carboxyborane)-dicopper (II), compound 1, demonstrated excellent activity at 2.5 mg/kg/day [5]. Preliminary
studies suggested that this derivative increase lipid excretion in the bile of rats [5]. Thus, the present study
extends the investigation of metal complexes of amine-carboxyboranes as hypolipidemic agents and their role
on biliary lipid excretion in rodents.
MATERIALS AND METHODS
Source of Material and Compounds
The synthesis and physical characteristics of these complexes has previously been reported:
Cu(u-(CH3)3NBH2COO)4.2(CH3)3NBH2COOH 1 [6] [Fe30((CH3)3NBH2COO)6(CH3OH)]NO3.CH3CN
2 [7], [Fe30((CH3)3NBH2COO)6(CH3OH)3]CI 3 [7], [Cr30((CH3)3
NBH2COO)6(H20)3]NO3.CH3OH.CH3CN 4 [7], cis[Co(en)2 ((CH3)3NBH2COO)2]C1-2.5 H20.0.5
CH3OH , [8], ZnC12.2 (CH3)3NBH2CN 6 [9], Ca((CH3)3 N.BH2COO) NO3.CH3 COCH3.0.5H20 7 [8],
Na(NH3.BH2CN)6I $ [10], Na(CH3)3NBH2COO’0.25CH3OH 9 [7], Na(CH3)2 NBH2 COO.0.45H20 10
[7], Na(CH3)2NBH3 11 [commercially available], NaBH3CN 12, Na2BH3COO 13, and Na2B10H10.H20
14 11]. Drugs were prepared in 1% carboxymethylcellulose and homogenized. Control animals were
maintained on 1% carboxymethylcellulose as a vehicle treated group.
All isotopes were purchased from New England Nuclear. Substrates and cofactors were obtained from Sigma
Chemical Co., and HPLC column and eluants were obtained from Waters Millipore Co.
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Hypolipidemic Screen in Mice
Test compounds were administered to CF-1 male mice (28g) at 8 mg/kg/day I.P, for 16 days. On days 9 and
16, blood was obtained by tail-vein bleeding and the serum was obtained by centrifugation at 3500 g x 10
min. The serum cholesterol levels were determined by a modification of the Liebermann-Burchard reaction
[12]. Serum triglyceride were determined using a commercial kit [Boehringer Mannheim Diagnostics].
Sprague Dawley male rats (~ 280g) were administered compound 1 at 2.5 mg/kg/day, orally and compound 4
at 8 mg/kg/day orally. Blood was collected on day 14 for serum lipid analysis. These doses were selected
based on a preliminary pilot study for the best efficacy of the indivivdual agents in rats.
Treatment of Rats
Bile Cannulation Studies. Sprague Dawley male rats (~300g) were administered compounds 1 at 2.5
mg/kg/day or 4 at 8 mg/kg/day by intubation tube, orally for 14 days. The rats were administered
chlorpromazine (25mg/kg) and anesthetized 30 minutes later with pentobarbital (22 mg/kg i.p.) [13], a
combination which reduces the amount of pentobarbital necessary to maintain anesthesia level over extended
periods of time without bronchial spasms. An incision was made just below the rib cage to expose the
stomach and the duodenum. Once the bile duct was indentified, a loose ligature was placed around it and the
duct was knicked. PE-10 plastic tubing was placed in the duct and tied in place. The bile was collected from
the control and treated groups over the next 6 hours while the animals were maintained under anesthesia.
Bile Lipid Levels. The flow rate of the bile was calculated for each group as ml/min. Aliquots were extracted
for lipids by the Folch et al. [14] and Bligh and Dyer [15] methods. Cholesterol [12], triglyceride [Bio-
Dynamics/bmc trigtyceride kit], neutral lipids [16], and phospholipid contents [17] were determined. Protein
concentrations were also determined [18].
HPLC Analysis of Bile Acids Content. Samples were frozen overnight and thawed. The bile lipids were
extracted with EtOH:water; [1:20] and filtered [19, 20]. Aliquots (250 l.tl) of the bile were added to 10 l.tl of
the internal standard (testosterone). Then 4.75 ml of hot analytical grade ethanol was added, vortexed, and
allowed to evaporate in a boiling water bath. The residues were dissolved in 250 [tl of the mobile phase A
[acetonitrile-methanol-0.03 M phosphate buffer, pH 3.4 (10:60:30 v/v/v)] and 100 I.tl was injected onto the
HPLC column (It Bondapak C18 column) (30 cm x 3.9 mm ID) (Waters) with a guard column (Bondapak
C18/Corasi) (Waters) eluted with mobile phase A. The flow rate was 0.5 ml/min (600 psi isobaric flow)
with detection at 210 nm. Standard bile acids (Sigma Chemical Co.) were purchased and were treated identical
as the bile biological samples.
Absorption from In Situ Duodenum Loops. Sprague Dawley male rats were treated at 8 mg/kg/day orally and
anesthesized as indicated above and the duodenum was isolated and knicked. Glass L-shaped cannulaes were
placed at the proximal end of the duodenum and 20 cm distally down the intestine [21 ]. The segment was
perfused with isotonic PBS buffer, pH 7.2 until the lumen was clear and all material expelled. Drug solution
(0.2 ml) (20 mg/kg) was placed in the loop with either 1, 2-3H- cholesterol (54.8 Ci/mol) or 2,4-3H- cholic
acid (25 mCi/mol) (21.tCi). Aliquots (50 ml) were periodically removed over the next 210 minutes and the
radioactivity determined using a Packard scintillation counter after correcting for quenching. The
disappearance of the isotope from the loop over time was plotted for the control and treated animals.
Hepatic and Small Intestinal Enzymatic Studies. Sprague Dawley male rats (~280 g) were administered drugs
1 at 2.5 mg/kg/day, or 4 at 8 mg/kg/day, orally for 14 days. On day 15, the animals were sacrificed and the
liver and small intestinal mucosa were excised. Homogenates (10%) in 0.25 M sucrose + 0.001 M EDTA,
pH 7.2 were prepared of the liver and small intestinal mucosa [22]. The following enzyme assays were
determined by literature techniques: ATP dependent citrate lyase [23], acetyl CoA synthetase [24], HMG-
CoA reductase [25,26], acyl-CoA cholesterol acyl transferase [27], neutral cholesterol ester hydrolases [28],
cholesterol-7a hydroxylase [29], acetyl CoA carboxylase [30], sn-glycerol-3-phosphate acyl transferase [31],
phosphatidylate phosphohydrolase [32] and lipoprotein lipase [33].
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Statistical Analysis
Data displayed in Tables 1-4 represent means _+ standard deviations. The Student’s "t" test was applied
between control groups and the individual drug treatment groups. The analysis of variance (ANOVA) was
applied among test drugs and is reported in the text only.
RESULTS
The calcium (7) and the chromium (4) complexes demonstrated the best hypolipidemic acivity in mice on day
16 after dosing at 8 mg/kg/day causing greater than 50% reduction of serum cholesterol levels [Table 1 ]. The
two iron complexes 2 and 3 and the sodium salts 9 and 14 caused at least 40% reduction of serum cholesterol
levels after 16 days administration. The serum triglyceride levels on day 16 were reduced most significantly,
i.e. greater than 50% by compounds 1 and 3. Compounds 2, 4, 6, 12, 13 and 15 caused at least 40 %
reduction of serum triglycedde levels in mice. In rats treated with compound I at 2.5 mg/kg/day, the serum
cholesterol levels on days 14 were reduced 49% and serum triglycedde levels were reduced 60% compared to
the control values. Compound 4 at 8 mg/kg/day reduced cholesterol values 51% and triglycedde levels 46%
after 14 days.
In rats treated with compound 1 at 2.5 mg/kg/day liver enzyme activities for acetyl CoA synthetase, ATP-
dependent citrate lyase, acyl CoA cholesterol acyl transferase, cholesterol-7-a hydroxylase, snglycerol-3-
phosphate acyl transferase and phosphatidylate phosphohydrolase were all inhibited after 14 days dosing [Table
2]. In the small intestinal mucosa after treatment with compound 1 the activities of acetyl CoA synthetase,
ATP- dependent citrate lyase, cholesterol-7-a hydrolase, acyl CoA cholesterol acyl transferase, neutral
cholesterol ester hydrolase, phosphatidylate phosphohydrolase and lipoprotein lipase were inhibited
significantly. Liver neutral cholesterol ester hydrolase and lipoprotein lipase activities were elevated after 14
days treatment.
Compound 4 after treatment in V.V0 at 8 mg/kg/day for 14 days significantly reduced liver acetyl CoA
synthetase, ATP-dependent citrate lyase, HMG CoA reductase, cholesterol 7-a-
TABLE
The Hypolipidemic Activity of Metal Complexes of Amine-Carboxyboranes and Related Compounds in CF-1
Male Mice Administered at 8 mg/kg/day I.P.
Percent of Control [X + S.D.]
Serum Cholesterol Serum Triglyceride
Compounds Day 9 Day 16 Day 16
Control 1% 100 + 6a 100 + 5b 100 + 7c
CMS
1 71 + 6* 63 + 5* 47 + 5*
2 58 + 5* 59 + 4* 54 + 6*
3 74 + 7 55 + 5* 48 + 6*
4 68 + 6* 45 -I, 4* 55 + 4*
5 89 + 7 60 + 5* 65 + 3*
6 85 + 5 71 + 6 50 + 5*
7 80 + 6 49 + 4* 67 + 6*
8 88 + 7 64 + 5* 72 + 5*
9 56 + 4* 53 + 3* 70 + 6*
10 108 + 6 63 + 5* 72 + 5*
11 103 +_ 6 77 + 7* 89 + 7
12 74 + 6* 74 + 5* 59 + 5*
13 76 + 4* 74 + 6* 57 + 6*
14 80 + 5 56 + 5* 81 + 5*
15 61 + 6 61 + 5* 53 + 5*
a 125 mg% b 128 mg% c 137 mg% * = P < 0.001 Student’s "t" test.
hydroxylase, acyl CoA cholesterol acyl transferase and sn-glycerol-3-phosphate acyl transferase activities
[Table 3].
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The compound reduced small intestinal mucosa ATP-dependent citate lyase, cholesterol-7-a hydroxylase, acyl
CoA cholesterol acyl transferase, sn-glycerol-3-phosphate acyl transferase, and lipoprotein lipase activities.
Liver and small intestine neutral cholesterol ester hydrolase, and liver lipoprotein lipase activities were
increased after dosing with compound 4 after 14 days.
In rats treated for 14 days with compound 1 the bile flow rate was increased whereas with compound 4 the
flow rate was decreased compared to the control value [Table 4]. Compound 1 increased biliary triglyceride
levels to 237% of the control and all biliary
TABLE 2
The Effects of Compound 1 on Sprague Dawley Rat Liver and Small Intestinal Mucosa Enzyme Activities
After 14 Day Oral Administration at 2.5 mg/kg/day orally.
Enzyme Assayed
N=6
Acetyl CoA synthetase
ATP-dep’t Citrate Lyase
HMG CoA reductase
Acyl CoA Chol.Acyl Trans
Cholesterol-7-hydroxylase
Chol. Ester Hydrolase
Acetyl CoA cboxylase
sn-Glycerol-3-phosphate
acyl transferase
Phosphatidylate
pho[phohydrolase
Lipoprotein Lipase
Percent of Control [X + S.D.]
Liver
Contr Treate
ol d
100 + 33 +
5a 5*
33 +
5*
100 +
6b
100 + 25 +
4c 6*
100 + 94 +
6e 6
100 + 34 +
5g 2*
100 + 54 +
3 4*
100 + 135 +
4k 7*
100 + 84 +
4m 6
100 + 34 +
5 3*
Small Intestinal Mucosa
Cont Treat
rol d
100 + 66 +
6b 5*
100+ 32 + 7
5d
100+ 93 +_ 6
7f
100 + 45 +
4h 4*
100+ 18+
4J 2*
100 + 63 +
51 4*
100+ 83 + 9
6n
100+ 88 +6
4P
100 + 27 +/-
6q 6*
100 + 127 +
5s 4*
100 +_. 56 +
6r 5*
100 +/- 53 +
6 6*
a = 10.1 mg acetyl CoA formed/g wet weight
b 5.27 mg acetyl CoA formed/g wet weight
c 9.2 mg citrate hydrolyzed/g wet weight
d 9.17 mg citrate hydrolyzed/g wet weight
e 103020 dpm/g wet tissue
g 86640 dpm/g wet tissue
289450 dpm/g wet tissue
k = 22443 dpm/g wet tissue
m 43000 dprn/g wet tissue
o 87620 dprn/g wet tissue
q 11 ug Pi released/g wet tissue
s 3112 dpm/g wet tissue
* P > 0.001 Student’s "t" test
f 113322 dpm/g wet tissue
h 64819 dpm/g wet tissue
j 23099 dpm/g wet tiisue
259099 dpm/g wet tissue
n 54892 dpm/g wet tissue
p 73219 dpm/g wet tissue
r 111 ug Pi released/g wet tissue
43128 dpm/g/wet tissue
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TABLE 3
The Effects of Compound 4 on Sprague Dawley Male Rat Liver and Small Intestinal Mucosa Enzyme
Activities After 14 Days at 8 mg/kg/day orally
Enzyme Assay
N=6
Acetyl CoA Synthetase
ATP Dep’t Citrate Lyase
HMG CoA Reductase
Acyl Chol. Acyl Transferase
Cholesterol-7-Hydroxylase
Cholesterol Ester Hydrolase
Acetyl CoA Carboxylase
sn-Glycerol-3-phosphate
Acyl Transferase
Phosphatidylate Phosphohydrolase
Lipoprotein Lipase
Percent Control [X + S.D.]
Liver Small Intestinal Mucosa
Contro Treate Contr Treated
d ol
100 + 4+ 100 + 88+
5 2* 6 6
100 + 7+ 100 + 45 +
4 4* 5 7*
100 + 50 + 100 + li7 +_
6 7* 7 8
100 + 36 +_ 100 + 51 +
5 2* 4 8*
100 + 69 + 100 + 65 +
3 7* 4 5*
100 + 8 + 100 + 237 +
4 7* 5 7*
100 + 4+ 100 + 99+
4 7 6 5
100 + 39:1: 100 + 16 +
5 5 4 4*
100 + 106:1: 100 + 85
6 6 6 6
100 + 127 +_ 100 + 53 +
5 4 6 6*
See Table 2 for standard values for control assays
lipids were within normal limits. Compound 4 afforded a 60% increase in biliary cholesterol and a 77%
increase in biliary
phospholipid levels after 14 days. The bile salt concentrations were also altered after drug treatment, e.g.
taurocholic, glycocholic, taurodeoxycholic, glycochenodeoxycholic and lithocholic acids were reduced by
compound while tauroursodeoxycholic, and glycourodeoxycholic acids were elevated and
taurochenodeoxycholic acid was not changed from the control value. Compounds 4 reduced the levels of
taurocholic, taurodeoxycholic, and glycourodeoxycholic acids.
Taurochendeoxycholic, glycocholic and tauroursodeoxycholic acids were elevated after treatment. Both
compounds retarded cholesterol absorption from isolated intestinal loops after 180 min [Fig. and 3]. Only
compound 4 blocked cholic acid absorption from the isolated loops after 180 min [Fig. 2 and 4].
TABLE 4
The Effects of the Metal Complexes Of Amine-Carboxyboranes on Biliary Lipids and Bile Acids of Sprague
Dawley Male Rats After 14 Days Administration Orally
Bile Lipids mg/dL + S.D.
N 6 Compound 1 Compound 4
Lipid Control 2.5 mg/kg/day 8 mg/kg/day
Cholesterol 113 + 5 104:1:4 181 + 6*
Tdglyceride 140 + 6 333 + 12 123 + 7* *
Neutral Lipids 294 + 8 297 + 10 306 + 11
Phospholipids 65 + 4 66 +_. 5 115 + 7
Protein 97 + 5 88 + 8 96 +
Flowrate ml/hr 0.62 1.18 0.31
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N=6
Tauroursodeoxycholic Acid
Glycoursodeoxycholic Acid
Taurocholic Acid
Glycocholic Acid
Taurodeoxycholic Acid
Lithocholic Acid
Taurochenodeoxycholic Acid
Glycochenodeoxycholic Acid
Total Bile Acids
Bile Acids g/ml + S.D.
Control Compound
2.50 6.54 +. 13
+.08
Compound
4
3.09 +.10
9.12 +.54 3.35 +.38
561+.34
1.53 0.01 +.01 0.00
+.06
0.62 0.02 +.01 0.86 +.03
+.04
0.50 0.01+.01 0.26 -I-.02
+.03
2.52 1.01 +.08 2.49 +. 11
+.15
0.24 0.22 +.02 0.52 +.03
+.01
0.09 0.01 +.01 0.11 +.02
+_.01
13.28 4- 16.94 +_.47 10.68 _+.32
.58
DISCUSSION
The copper, chromium, iron and zinc metal complexes of amine-carboxyboranes were generally more effective
than sodium and cobalt complexes in reducing both serum cholesterol and triglyceride levels in mice after 16
days at 8 mg/kg/day I.P. The copper complex 1 also demonstrated good activity at 2.5 mg/kg/day, orally in
rats after 14 days administration. These complexes were not the sterotype HMG CoA reductase enzyme
inhibitor. Rather a number of regulatory enzymes for de n0v0 synthesis of fatty acids, cholesterol,
cholesterol esters and triglyceride were reduced by the complexes after in administration in both the liver
and small intestinal mucosa. The reduction of these enzyme activites by the agents was of a magnitude to
account for the observed reduction of serum lipids afforded by the agents. One of the advantages of these
complexes was the inhibition of acyl CoA cholesterol acyl transferase activity thus reducing the formation of
cholesterol esters. Coupled with this effect of the agents was the accelerated activity of neutral cholesterol
ester hydrolase afforded by the complexes which would lead to accelerated break down of cholesterol esters
releasing free cholesterol to combine to HDL to return to the liver for excretion through the bile. If these
enzymes are affected by the same manner in the aorta foam cells of the endothelium the formation of aorta
plaques should be reduced as well as the incidence of atherosclerosis. A second mode of action of the metal
complexes of amine-carboxyborane derivatives is the modulation of biliary excretion and enterohepatic
circulation of lipids. Compound 1 increased bile flow and excretion of triglycerides whereas compound 4
accelerated excretion of cholesterol and phospholipids similiar to clofibrate effects. The bile acid profile was
altered after drug treatment. However, there was no indication that large amounts of lithocholic acid was
present which in rats is highly cholestatic [34]. Thus, there is no reason to think that these hypolipidemic
agents may cause the formation of gall stones. Changes in bile acids can cause choleresis for example in
decreasing order dehydrocholic > chenodeoxycholic > cholic acid > taurocholic acid > deoxycholic >
glycocholic acid [35]. Compound 1 resulted in increases in glycourodeoxycholic acid and
tauroursodeoxycholic acid which may have influenced the increase in bile flow observed for this agent.
Compound 4 demonstrated no such large increases in any of the bile acids and no increase in bile flow. Gall
stone formation has been linked with high levels of hepatic HMG CoA reductase activity and low levels of
cholesterol-7-a hydroxylase activity. Neither compound created elevatedHMG CoA reductase activity but both
caused reduced cholesterol-7-a hydroxylase activity. This latter enzyme is the regulatory enzyme for the
conversion of cholesterol to bile acids and should affect the bile acid profile if reduced in activity.
One mode of action of the metal complexes of amine carboxyborane derivatives was to block the resorption of
cholesterol from the intestine thus returning it to the liver via the portal vein. Blocking this process is a
viable mode of action of hypolipidemic agents, colestipol and cholestyramine, and would be additive with the
other mode of action of the derivatives of inhibiting regulatory enzyme activities of de novo synthesis of
lipids in the liver and small intestinal mucosa.
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